Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
28
RGBP Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
32.11%
Day range:
$0.0084 - $0.0109
52-week range:
$0.0038 - $0.1169
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.62x
P/B ratio:
--
Volume:
1.3M
Avg. volume:
817.8K
1-year change:
-91.6%
Market cap:
$464K
Revenue:
$236.6K
EPS (TTM):
-$0.15
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RGBP
Regen Biopharma, Inc.
|
-- | -- | -- | -- | -- |
|
AGEN
Agenus, Inc.
|
$80.4M | $2.20 | 144.6% | -70.59% | $12.33 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$1.4M | -$0.42 | 19.84% | -177.23% | $9.00 |
|
CRIS
Curis, Inc.
|
$2.9M | -$0.60 | -2.86% | -65.51% | $14.00 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RGBP
Regen Biopharma, Inc.
|
$0.0084 | -- | $464K | -- | $0.00 | 0% | 0.62x |
|
AGEN
Agenus, Inc.
|
$3.72 | $12.33 | $126.5M | -- | $0.00 | 0% | 0.94x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$5.72 | $9.00 | $207.8M | -- | $0.00 | 0% | 47.45x |
|
CRIS
Curis, Inc.
|
$1.18 | $14.00 | $15.3M | -- | $0.00 | 0% | 1.13x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.81 | $11.00 | $145.6M | 26.04x | $0.00 | 0% | 2.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RGBP
Regen Biopharma, Inc.
|
-21.68% | 0.903 | 65.63% | 0.03x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.383 | 285.06% | 0.03x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
216.44% | 3.715 | 164.57% | 0.11x |
|
CRIS
Curis, Inc.
|
192.35% | 3.282 | 144.76% | 0.62x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RGBP
Regen Biopharma, Inc.
|
-- | -$40.8K | -- | -- | -69.04% | -$56K |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$789K | -$7.8M | -57.86% | -- | -670.92% | -$4.5M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Regen Biopharma, Inc. vs. Competitors
-
Which has Higher Returns RGBP or AGEN?
Agenus, Inc. has a net margin of -283.08% compared to Regen Biopharma, Inc.'s net margin of -116.82%. Regen Biopharma, Inc.'s return on equity of -- beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RGBPRegen Biopharma, Inc.-- -$0.01 -$4.8M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About RGBP or AGEN?
Regen Biopharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 231.54%. Given that Agenus, Inc. has higher upside potential than Regen Biopharma, Inc., analysts believe Agenus, Inc. is more attractive than Regen Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RGBPRegen Biopharma, Inc.0 0 0 AGENAgenus, Inc.2 1 0 -
Is RGBP or AGEN More Risky?
Regen Biopharma, Inc. has a beta of 3.056, which suggesting that the stock is 205.621% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.01%.
-
Which is a Better Dividend Stock RGBP or AGEN?
Regen Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regen Biopharma, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGBP or AGEN?
Regen Biopharma, Inc. quarterly revenues are $59.1K, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Regen Biopharma, Inc.'s net income of -$167.3K is lower than Agenus, Inc.'s net income of $63.9M. Notably, Regen Biopharma, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regen Biopharma, Inc. is 0.62x versus 0.94x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGBPRegen Biopharma, Inc.0.62x -- $59.1K -$167.3K AGENAgenus, Inc.0.94x -- $30.2M $63.9M
-
Which has Higher Returns RGBP or AIM?
AIM ImmunoTech has a net margin of -283.08% compared to Regen Biopharma, Inc.'s net margin of -10571.43%. Regen Biopharma, Inc.'s return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital RGBPRegen Biopharma, Inc.-- -$0.01 -$4.8M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About RGBP or AIM?
Regen Biopharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Regen Biopharma, Inc., analysts believe AIM ImmunoTech is more attractive than Regen Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RGBPRegen Biopharma, Inc.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is RGBP or AIM More Risky?
Regen Biopharma, Inc. has a beta of 3.056, which suggesting that the stock is 205.621% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock RGBP or AIM?
Regen Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regen Biopharma, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGBP or AIM?
Regen Biopharma, Inc. quarterly revenues are $59.1K, which are larger than AIM ImmunoTech quarterly revenues of $35K. Regen Biopharma, Inc.'s net income of -$167.3K is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Regen Biopharma, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regen Biopharma, Inc. is 0.62x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGBPRegen Biopharma, Inc.0.62x -- $59.1K -$167.3K AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns RGBP or ARMP?
Armata Pharmaceuticals, Inc. has a net margin of -283.08% compared to Regen Biopharma, Inc.'s net margin of -2301.55%. Regen Biopharma, Inc.'s return on equity of -- beat Armata Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RGBPRegen Biopharma, Inc.-- -$0.01 -$4.8M ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M -
What do Analysts Say About RGBP or ARMP?
Regen Biopharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 57.34%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Regen Biopharma, Inc., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Regen Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RGBPRegen Biopharma, Inc.0 0 0 ARMPArmata Pharmaceuticals, Inc.1 0 0 -
Is RGBP or ARMP More Risky?
Regen Biopharma, Inc. has a beta of 3.056, which suggesting that the stock is 205.621% more volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.
-
Which is a Better Dividend Stock RGBP or ARMP?
Regen Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regen Biopharma, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGBP or ARMP?
Regen Biopharma, Inc. quarterly revenues are $59.1K, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Regen Biopharma, Inc.'s net income of -$167.3K is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Regen Biopharma, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regen Biopharma, Inc. is 0.62x versus 47.45x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGBPRegen Biopharma, Inc.0.62x -- $59.1K -$167.3K ARMPArmata Pharmaceuticals, Inc.47.45x -- $1.2M -$26.7M
-
Which has Higher Returns RGBP or CRIS?
Curis, Inc. has a net margin of -283.08% compared to Regen Biopharma, Inc.'s net margin of -243.36%. Regen Biopharma, Inc.'s return on equity of -- beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital RGBPRegen Biopharma, Inc.-- -$0.01 -$4.8M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About RGBP or CRIS?
Regen Biopharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1086.44%. Given that Curis, Inc. has higher upside potential than Regen Biopharma, Inc., analysts believe Curis, Inc. is more attractive than Regen Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RGBPRegen Biopharma, Inc.0 0 0 CRISCuris, Inc.4 0 0 -
Is RGBP or CRIS More Risky?
Regen Biopharma, Inc. has a beta of 3.056, which suggesting that the stock is 205.621% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 4.025, suggesting its more volatile than the S&P 500 by 302.512%.
-
Which is a Better Dividend Stock RGBP or CRIS?
Regen Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regen Biopharma, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGBP or CRIS?
Regen Biopharma, Inc. quarterly revenues are $59.1K, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Regen Biopharma, Inc.'s net income of -$167.3K is higher than Curis, Inc.'s net income of -$7.7M. Notably, Regen Biopharma, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regen Biopharma, Inc. is 0.62x versus 1.13x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGBPRegen Biopharma, Inc.0.62x -- $59.1K -$167.3K CRISCuris, Inc.1.13x -- $3.2M -$7.7M
-
Which has Higher Returns RGBP or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -283.08% compared to Regen Biopharma, Inc.'s net margin of 13.19%. Regen Biopharma, Inc.'s return on equity of -- beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital RGBPRegen Biopharma, Inc.-- -$0.01 -$4.8M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About RGBP or PLX?
Regen Biopharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 507.74%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Regen Biopharma, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Regen Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RGBPRegen Biopharma, Inc.0 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is RGBP or PLX More Risky?
Regen Biopharma, Inc. has a beta of 3.056, which suggesting that the stock is 205.621% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock RGBP or PLX?
Regen Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regen Biopharma, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGBP or PLX?
Regen Biopharma, Inc. quarterly revenues are $59.1K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Regen Biopharma, Inc.'s net income of -$167.3K is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Regen Biopharma, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 26.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regen Biopharma, Inc. is 0.62x versus 2.30x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGBPRegen Biopharma, Inc.0.62x -- $59.1K -$167.3K PLXProtalix Biotherapeutics, Inc.2.30x 26.04x $17.9M $2.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
40
HUT alert for Dec 17
Hut 8 Corp. [HUT] is up 12.08% over the past day.
Sell
39
SMX alert for Dec 17
SMX (Security Matters) Plc [SMX] is up 22.55% over the past day.
Sell
45
ZBIO alert for Dec 17
Zenas BioPharma, Inc. [ZBIO] is down 2.33% over the past day.
